Results 11 to 20 of about 4,586,589 (282)

Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead

International Journal of Molecular Sciences
Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. The FDA granted traditional approval to lecanemab in July 2023, and the European Medicines Agency approved it in late 2024 with specific genetic restrictions; meanwhile, donanemab received FDA approval in July 2024 and EMA ...
Vasileios Papaliagkas
openaire   +4 more sources

Anti-amyloid antibody therapies in Alzheimer’s disease

Brain, 2023
AbstractAfter years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease, consistent evidence in support of clinical efficacy was finally presented for a monoclonal antibody targeting the amyloid-β protofibrils. In addition to meeting the primary outcome of slowing clinical disease progression over 18 months, secondary ...
Perneczky, Robert, Jessen, Frank, Grimmer, Timo, Levin, Johannes, Floeel, Agnes, Peters, Oliver, Froelich, Lutz   +6 more
openaire   +4 more sources

Modeling an Anti-Amyloid Combination Therapy for Alzheimer’s Disease [PDF]

Science Translational Medicine, 2010
Simultaneous reduction of two of the enzymes that create the plaque-forming peptide β-amyloid in Alzheimer’s disease ameliorates symptoms in aged mice better than elimination of either enzyme alone.
Vivian W, Chow, Alena V, Savonenko, Tatiana, Melnikova, Hyunsu, Kim, Donald L, Price, Tong, Li, Philip C, Wong   +6 more
openaire   +2 more sources

A Chemical Perspective to the Anti-Amyloid Action of Compounds and a Nanoparticle Based Assay for Screening Amyloid Inhibitors [PDF]

, 2020
Aggregation of amyloid beeta 1-42 (Aβ42) peptide causes the formation of clustered deposits knows as amyloid plaques in the brain which leads to neuronal dysfunction and memory loss and associated with many neurological disorders including Alzheimer’s ...
Nidhi, Gour, Bharti, Koshti
core   +1 more source

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
The recent success of disease‐modifying anti‐amyloid monoclonal antibodies in slowing Alzheimer's disease (AD) symptoms has been an exciting step forward for the field.
Jennifer Erichsen, Suzanne Craft
doaj   +1 more source

Nonsteroidal Anti-Inflammatory Drugs and Ectodomain Shedding of the Amyloid Precursor Protein [PDF]

, 2008
Background: Epidemiological studies have suggested that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of Alzheimer's disease (AD).
Hermann Esselmann, Julia Ness, Leuchtenberger, Stefanie, Maler, Juan, Pietrzik, Claus U., Esselmann, Hermann, Sascha Weggen, Ness, Julia, Stefan F. Lichtenthaler, Czirr, Eva, Claus U. Pietrzik, Jens Wiltfang, Lichtenthaler, Stefan F., Stefanie Leuchtenberger, Weggen, Sascha, Juan Maler, Wiltfang, Jens, Eva Czirr   +17 more
core   +1 more source

Destruxin E Decreases Beta-Amyloid Generation by Reducing Colocalization of Beta-Amyloid-Cleaving Enzyme 1 and Beta-Amyloid Protein Precursor [PDF]

, 2009
Alzheimer-disease-associated beta-amyloid (A beta) is produced by sequential endoproteolysis of beta-amyloid protein precursor (beta APP): the extracellular portion is shed by cleavage in the juxtamembrane region by beta-amyloid-cleaving enzyme (BACE ...
Nakano, Yuko, Willem, Michael, Kudo, Takashi, Minagawa, Kazuyuki, Jiang, Jingwei, Okochi, Masayasu, Takemoto, Hiroshi, Hosono, Motoko, Nishimura, Masaki, Takeda, Masatoshi, Itoh, Naohiro, Nishigaki, Atsuko, Hasegawa, Hiroshi, Sakaguchi, Gaku, Kato, Akira, Haass, Christian, Tanaka, Toshihisa, Yanagida, Kanta, Mori, Kohji, Nakayama, Taisuke, Kikuchi, Jyunko, Dohi, Keiji, Takinami, Yoshihiko, Katoh, Takaaki, Nishitomi, Kouhei, Morihara, Takashi, Tagami, Shinji, Fukumori, Akio   +27 more
core   +1 more source

IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. [PDF]

, 2015
IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis and cardiovascular disease (CVD) in ...
Davari, M, Yiannis Ioannou, Isenberg, D, Paul Bassett, Rahman, A, David Isenberg, Anisur Rahman, Maria Davari, Alber, KF, Ioannou, Y, Oliver Leach, Giles, I, Bassett, P, Karim Alber, Ian Giles, Leach, O, Sara Croca, Chambers, S, Croca, S, Sharon Chambers   +19 more
core   +1 more source

Amyloid and tau in the brain in sporadic Alzheimer’s disease: defining the chicken and the egg [PDF]

, 2014
In the October 2013 issue of Acta Neuropathologica there were three very interesting articles on: Amyloid or tau: the chicken or the egg? In the first article, David Mann and John Hardy argued that the deposition of aggregated amyloid β (Aβ) protein in ...
Cheryl A. Hawkes, Roy O. Weller, Roxana O. Carare, Hawkes, Cheryl A., Carare, Roxana O., Weller, Roy O.   +5 more
core   +1 more source

Cerebral Amyloid Angiopathy-Related Inflammation: Report of a Case with Very Difficult Therapeutic Management

Case Reports in Neurological Medicine, 2015
Background. Cerebral amyloid angiopathy-related inflammation (CAA-ri) results from autoimmune response to beta-amyloid deposits in cerebral vessels. Its clinical course and complications have seldom been described in literature. Case Report. In a patient
Francesca Crosta, Berardino Orlandi, Federica De Santis, Gianni Passalacqua, Jacopo C. DiFrancesco, Fabrizio Piazza, Alessia Catalucci, Giovambattista Desideri, Carmine Marini   +8 more
doaj   +1 more source